


## DHODH-IN-26

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-158023   |
| <b>Molecular Formula:</b> | C <sub>44</sub> H <sub>34</sub> BrF <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P          |
| <b>Molecular Weight:</b>  | 787.63  |
| <b>Target:</b>            | Reactive Oxygen Species; Dihydroorotate Dehydrogenase; Ferroptosis                        |
| <b>Pathway:</b>           | Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Apoptosis                      |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

| Description      | DHODH-IN-26 (compound B2) is a mitochondria-targeting DHODH inhibitor. DHODH-IN-26 shows anticancer activity, triggers the formation of reactive oxygen species (ROS), promotes mitochondrial lipid peroxidation, and induces ferroptosis <sup>[1]</sup> . |  |
|------------------|--|--|
| In Vitro         | DHODH-IN-26 (compound B2) (0.01-100 μM, 72 h) inhibits cell growth of 4T1, B16F10, U251, GL261, SH-SY5Y, U87, and A375 cells <sup>[1]</sup> .  |  |
|                  | DHODH-IN-26 (50 and 100 nM) inhibits colony formation in B16F10 and A375 cells <sup>[1]</sup> .  |  |
|                  | DHODH-IN-26 (50 and 100 nM, 48 h) decreases the expression of PD-L1 in B16F10 and A375 cells <sup>[1]</sup> .  |  |
|                  | MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |  |
|                  | Cell Viability Assay <sup>[1]</sup>  |  |
|                  | Cell Line:   | 4T1, B16F10, U251, GL261, SH-SY5Y, U87, and A375 cells |
|                  | Concentration:   | 0.01, 0.1, 1, 10 and 100 μM                            |
|                  | Incubation Time:   | 72 h   |
|                  | Result:  | Inhibited cell growth.                                 |
|                  | Western Blot Analysis <sup>[1]</sup>   |  |
| Cell Line:       | B16F10 and A375 cells  |  |
| Concentration:   | 50 and 100 nM  |  |
| Incubation Time: | 48 h   |  |
| Result:          | Decreased the expression of PD-L1.   |  |
| In Vivo          | DHODH-IN-26 (compound B2) (intraperitoneal injection, 50 mg/kg for 14 days) inhibits tumor growth in B16F10 xenograft model in C57BL/6 mice <sup>[1]</sup> .   |  |
|                  | MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |  |
| Animal Model:    | B16F10 xenograft model in C57BL/6 mice <sup>[1]</sup>  |  |

|                 |                       |
|-----------------|-----------------------|
| Dosage:         | 50 mg/kg              |
| Administration: | I.p.; for 14 days     |
| Result:         | Reduced tumor volume. |

## REFERENCES

[1]. Hai Y, et al. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression. *Pharmacol Res.* 2024;202:107115.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA